Abstract
Bacille Calmette-Guérin (BCG) vaccination supposedly imparts and augments “trained immunity” that cross-protects against multiple unrelated pathogens and enhances general immune surveillance. Gradual reductions in tuberculosis burden over the last 3-5 decades have resulted in the withdrawal of BCG vaccination mandates from developed industrialized countries while reducing to a single neonatal shot in the rest. Concurrently, a steady increase in early childhood Brain and CNS (BCNS) tumors has occurred. Though immunological causes of pediatric BCNS cancer are suspected, the identification of a causal protective variable with an intervention potential has remained elusive. An examination of the countries with contrasting vaccination policies indicates significantly lower BCNS cancer incidence (per hundred-thousand) in countries following neonatal BCG inoculations (n=146) vs. non-BCG countries (n=33) [Mean: 1.26 vs. 2.64; Median: 0.985 vs. 2.8; IQR: 0.31–2.0 vs. 2.4–3.2; P=<0.0001(two-tailed)]. Remarkably, natural Mycobacterium spp. exposure likelihood is negatively correlated with pediatric BCNS cancer incidences in all affected countries [r(154): —0.6085, P=<0.0001]. Seemingly, neonatal BCG vaccination and natural “boosting” are associated with a 15-20-fold lower BCNS cancer incidence. We attempt to synthesize existing evidence implying the immunological basis of early childhood BCNS cancer incidences and briefly indicate possible causes that could have precluded objective analysis of the existing data in the past. A comprehensive evaluation of immune training as a potential protective variable through well-designed controlled clinical trials or registry-based studies as feasible may be warranted for its potential applications in reducing childhood BCNS cancer incidences.
Statement of Significance Potential causal protective variable for childhood Brain and other CNS (BCNS) tumors has eluded discovery. Neonatal BCG vaccination and boosting by Mycobacterium tuberculosis complex exposure seem associated with over 15-20 times lower BCNS cancer incidences. Data suggests neonatal BCG vaccination followed by “boosting” may be preventive for early childhood BCNS cancer incidences.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript and available online
